3 stocks that soared stupendously this week  6-20-14
Upcoming SlideShare
Loading in...5
×
 

3 stocks that soared stupendously this week 6-20-14

on

  • 19,344 views

3 of the week's biggest health-care stocks

3 of the week's biggest health-care stocks

Statistics

Views

Total Views
19,344
Views on SlideShare
872
Embed Views
18,472

Actions

Likes
3
Downloads
1
Comments
1

10 Embeds 18,472

http://www.fool.com 18244
http://m.fool.com 199
http://www.barchart.com 8
http://barchartjson.websol.barchart.com 8
https://cms.fool.com 5
http://translate.googleusercontent.com 4
http://www.greenwichtime.com 1
http://www.seattlepi.com 1
http://www.mysanantonio.com 1
http://www2.barchart.com 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

3 stocks that soared stupendously this week  6-20-14 3 stocks that soared stupendously this week 6-20-14 Presentation Transcript

  • 3 Stocks That Soared Stupendously This Week
  • The market enjoyed yet another great week. Several health-care stocks really set the pace. Here are three that soared by 25% and more.
  • Shares of the clinical stage biotech surged 56% this week. Bluebird Bio (Nasdaq:BLUE) Source: Yahoo! Finance
  • • Bluebird reported positive early results from a phase 1 / 2 study of LentiGlobin in treating beta-thalassemia, a rare genetic blood disorder • The first two patients in the study were blood transfusion independent as of day 10 and 12, respectively with no drug-related adverse events, according to the company • This marks very encouraging news for Bluebird, which also has a couple of other mid-stage studies underway for LentiGlobin • It’s also potentially good news for the estimated 228,000 patients suffering from the rare disease Why Bluebird Bio shares flew
  • Shares of the biopharmaceutical firm skyrocketed 51% higher for the week. Insmed (Nasdaq:INSM) Source: Yahoo! Finance
  • • Insmed announced that the FDA granted breakthrough status designation to Arikayce • The drug targets treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease who are treatment refractory • Breakthrough status designation stemmed from the company’s phase 2 study of Arikayce, which produced some positive results even though the primary endpoint wasn’t met • Insmed reported good results last year from a phase 3 study of Arikayce conducted in Europe and Canada targeting treatment of lung infection in cystic fibrosis patients Why Insmed shares ignited
  • Shares of the medical device maker soared 25% higher this week. Covidien (NYSE:COV) Source: Yahoo! Finance
  • • Medtronic (NYSE:MDT) announced on Monday that it planned to buy Covidien for $42.9 billion • The deal expands Medtronic’s product lineup and should produce $850 million of annual cost synergies by 2018 • It also helps significantly on the tax front, with Medtronic moving to tax- friendly Ireland, where Covidien is currently based Why Covidien shares crushed the market
  • • Covidien has enjoyed its big pop and likely won’t move up much more now • Further good news for Arikayce would keep positive momentum going for Insmed • The best pick for continuing the winning ways, though, appears to be Bluebird Bio • While the data is still early for LentiGlobin, it’s also very promising • Bluebird stands a solid chance to keep flapping its wings higher Best pick to keep soaring?
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!